chr3-52457855-C-G
Position:
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_007184.4(NISCH):āc.106C>Gā(p.Gln36Glu) variant causes a missense change. The variant allele was found at a frequency of 0.0000363 in 1,459,290 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: not found (cov: 33)
Exomes š: 0.000036 ( 0 hom. )
Consequence
NISCH
NM_007184.4 missense
NM_007184.4 missense
Scores
3
16
Clinical Significance
Conservation
PhyloP100: 5.24
Genes affected
NISCH (HGNC:18006): (nischarin) This gene encodes a nonadrenergic imidazoline-1 receptor protein that localizes to the cytosol and anchors to the inner layer of the plasma membrane. The orthologous mouse protein has been shown to influence cytoskeletal organization and cell migration by binding to alpha-5-beta-1 integrin. In humans, this protein has been shown to bind to the adapter insulin receptor substrate 4 (IRS4) to mediate translocation of alpha-5 integrin from the cell membrane to endosomes. Expression of this protein was reduced in human breast cancers while its overexpression reduced tumor growth and metastasis; possibly by limiting the expression of alpha-5 integrin. In human cardiac tissue, this gene was found to affect cell growth and death while in neural tissue it affected neuronal growth and differentiation. Alternative splicing results in multiple transcript variants encoding differerent isoforms. Some isoforms lack the expected C-terminal domains of a functional imidazoline receptor. [provided by RefSeq, Jan 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -6 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.12114066).
BS2
High AC in GnomAdExome4 at 53 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NISCH | NM_007184.4 | c.106C>G | p.Gln36Glu | missense_variant | 2/21 | ENST00000345716.9 | NP_009115.3 | |
NISCH | NM_001276293.2 | c.106C>G | p.Gln36Glu | missense_variant | 2/13 | NP_001263222.2 | ||
NISCH | NM_001276294.2 | c.106C>G | p.Gln36Glu | missense_variant | 2/14 | NP_001263223.2 | ||
NISCH | XM_047447373.1 | c.106C>G | p.Gln36Glu | missense_variant | 2/18 | XP_047303329.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NISCH | ENST00000345716.9 | c.106C>G | p.Gln36Glu | missense_variant | 2/21 | 1 | NM_007184.4 | ENSP00000339958.4 | ||
NISCH | ENST00000479054.5 | c.106C>G | p.Gln36Glu | missense_variant | 3/22 | 1 | ENSP00000418232.1 | |||
NISCH | ENST00000488380.5 | c.106C>G | p.Gln36Glu | missense_variant | 2/13 | 1 | ENSP00000417812.1 | |||
NISCH | ENST00000420808.2 | c.106C>G | p.Gln36Glu | missense_variant | 2/14 | 5 | ENSP00000392484.2 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
GnomAD4 exome AF: 0.0000363 AC: 53AN: 1459290Hom.: 0 Cov.: 30 AF XY: 0.0000400 AC XY: 29AN XY: 725510
GnomAD4 exome
AF:
AC:
53
AN:
1459290
Hom.:
Cov.:
30
AF XY:
AC XY:
29
AN XY:
725510
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 19, 2024 | The c.106C>G (p.Q36E) alteration is located in exon 2 (coding exon 2) of the NISCH gene. This alteration results from a C to G substitution at nucleotide position 106, causing the glutamine (Q) at amino acid position 36 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
DEOGEN2
Benign
T;T;.;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
.;D;D;D
M_CAP
Benign
T
MetaRNN
Benign
T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
N;N;.;N
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N;N;N
REVEL
Benign
Sift
Benign
T;T;T;T
Sift4G
Benign
T;T;T;T
Polyphen
B;B;B;.
Vest4
MVP
MPC
0.46
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at